Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay

Translational Research

Volumn 177, Issue , 2016, Pages 19-30.e5

  Garbowski, Maciej W ^a,b   Ma, Yongmin ^c,d   Fucharoen, Suthat ^e   Srichairatanakool, Somdet ^f   Hider, Robert ^c   Porter, John B ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^e MAHIDOL UNIVERSITY   (Thailand)

^f Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

APOTRANSFERRIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON CHELATE; NITRILOTRIACETIC ACID; NON TRANSFERRIN BOUND IRON; TRANSFERRIN; UNCLASSIFIED DRUG; IRON; IRON CHELATING AGENT; MICROSPHERE;

ARTICLE; ASSAY; BETA THALASSEMIA; BLACKFAN DIAMOND ANEMIA; CHELATION THERAPY; CONTROLLED STUDY; EBETA THALASSEMIA; ERYTHROPOIESIS; FERRITIN BLOOD LEVEL; FLOW CYTOMETRY; FLUORESCENT BEAD LINKED FLOW CYTOMETRIC ASSAY; HUMAN; IRON STORAGE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NITRILOTRIACETATE ASSAY; PRIORITY JOURNAL; SIDEROBLASTIC ANEMIA; SPLENECTOMY; THALASSEMIA; BIOASSAY; FLUORESCENCE; METABOLISM; PROCEDURES; REGRESSION ANALYSIS;

BIOLOGICAL ASSAY; FLUORESCENCE; HUMANS; IRON; IRON CHELATING AGENTS; MICROSPHERES; NITRILOTRIACETIC ACID; REGRESSION ANALYSIS; TRANSFERRIN;

EID: 84979681515     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.05.005     Document Type: Article

References (38)

1. 1 Hershko, C., Graham, G., Bates, G.W., Rachmilewitz, E., Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 40 (1978), 255–263.
2. 2 Porter, J.B., Abeysinghe, R.D., Marshall, L., Hider, R.C., Singh, S., Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 88 (1996), 705–713.
3. 3 Gosriwatana, I., Loreal, O., Lu, S., Brissot, P., Porter, J., Hider, R.C., Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin. Anal Biochem 273 (1999), 212–220.
4. 4 Loréal, O., Gosriwatana, I., Guyader, D., Porter, J., Brissot, P., Hider, R.C., Determination of non-transferrin-bound iron in genetic hemochromatosis using a new HPLC-based method. J Hepatol 32 (2000), 727–733.
5. 5 Porter, J.B., Walter, P.B., Neumayr, L.D., et al. Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused Diamond Blackfan anaemia with sickle cell and thalassaemia patients. Br J Haematol 167 (2014), 692–696.
6. 6 Brissot, P., Wright, T.L., Ma, W.L., Weisiger, R.A., Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 76 (1985), 1463–1470.
7. 7 Wang, C.Y., Knutson, M.D., Hepatocyte divalent metal-ion transporter-1 is dispensable for hepatic iron accumulation and non-transferrin-bound iron uptake in mice. Hepatology 58 (2013), 788–798.
8. 8 Jenkitkasemwong, S., Wang, C.Y., Coffey, R., et al. SLC39A14 is required for the development of hepatocellular iron overload in murine models of hereditary hemochromatosis. Cell Metab 22 (2015), 138–150.
9. 9 Bergeron, C., Kovacs, K., Pituitary siderosis. A histologic, immunocytologic, and ultrastructural study. Am J Pathol 93 (1978), 295–309.
10. 10 Simpson, R.J., Konijn, A.M., Lombard, M., Raja, K.B., Salisbury, J.R., Peters, T.J., Tissue iron loading and histopathological changes in hypotransferrinaemic mice. J Pathol 171 (1993), 237–244.
11. 2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat Med 9 (2003), 1187–1194.
12. 12 Oudit, G.Y., Trivieri, M.G., Khaper, N., Liu, P.P., Backx, P.H., Role of L-type Ca2+ channels in iron transport and iron-overload cardiomyopathy. J Mol Med (Berl) 84 (2006), 349–364.
13. 13 Evans, R.W., Rafique, R., Zarea, A., et al. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem 13 (2008), 57–74.
14. 14 Silva, A.M., Kong, X., Parkin, M.C., Cammack, R., Hider, R.C., Iron(III) citrate speciation in aqueous solution. Dalton Trans 40 (2009), 8616–8625.
15. 15 Silva, A.M., Hider, R.C., Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation. Biochim Biophys Acta 1794 (2009), 1449–1458.
16. 16 Hider, R.C., Silva, M.N., Podinovskaia, M., Ma, Y., Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron. Ann N Y Acad Sci 1202 (2010), 94–99.
17. 17 Aydinok, Y., Evans, P., Manz, C.Y., Porter, J.B., Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response. Haematologica 97 (2012), 835–841.
18. 18 de Swart, L., Hendriks, J.C., van der Vorm, L.N., et al. Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders. Haematologica 101 (2016), 38–45.
19. 19 Singh, S., Hider, R.C., Porter, J.B., A direct method for quantification of non-transferrin-bound iron. Anal Biochem 186 (1990), 320–323.
20. 20 Esposito, B.P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C., Cabantchik, Z.I., Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102 (2003), 2670–2677.
21. 21 Breuer, W., Ermers, M.J., Pootrakul, P., Abramov, A., Hershko, C., Cabantchik, Z.I., Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 97 (2001), 792–798.
22. 22 Breuer, W., Cabantchik, Z.I., A fluorescence-based one-step assay for serum non-transferrin-bound iron. Anal Biochem 299 (2001), 194–202.
23. 23 Ma, Y., Podinovskaia, M., Evans, P.J., et al. A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry. Biochem J 463 (2014), 351–362.
24. 24 Evans, R.W., Williams, J., The electrophoresis of transferrins in urea/polyacrylamide gels. Biochem J 189 (1980), 541–546.
25. 25 Garbowski, M.W., Carpenter, J.P., Smith, G., et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson, 16, 2014, 40.
26. 26 St. Pierre, T.G., Clark, P.R., Chua-anusorn, W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105 (2005), 855–861.
27. 27 Carpenter, J.-P., He, T., Kirk, P., et al. On T2* magnetic resonance and cardiac iron. Circulation 123 (2011), 1519–1528.
28. 28 Bland, J.M., Altman, D.G., Measuring agreement in method comparison studies. Stat Methods Med Res 8 (1999), 135–160.
29. 29 Breuer, W., Ronson, A., Slotki, I.N., Abramov, A., Hershko, C., Cabantchik, Z.I., The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 95 (2000), 2975–2982.
30. 30 Walter, P.B., Macklin, E.A., Porter, J., et al. Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica 93 (2008), 817–825.
31. 31 Evans, P., Kayyali, R., Hider, R.C., Eccleston, J., Porter, J.B., Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res 156 (2010), 55–67.
32. 32 Srichairatanakool, S., Kemp, P., Porter, J.B., Evidence for “shuttle” effect of NTBI onto desferrioxamine in thalassaemic plasma in the presence of NTA. Paper presented at: International Symposium: Iron in Biology and Medicine, 1997 St. Malo, France; Abstract no. 210.
33. 33 Ito, S., Ikuta, K., Kato, D., et al. Non-transferrin-bound iron assay system utilizing a conventional automated analyzer. Clin Chim Acta 437 (2014), 129–135.
34. 34 Makino, T., Nakamura, K., Takahara, K., Potential problems in the determination of serum non-transferrin-bound iron using nitrilotriacetic acid and ultrafiltration. Clin Chim Acta 429 (2014), 12–13.
35. 35 Huebers, H.A., Finch, C., The physiology of transferrin and transferrin receptors. Physiol Rev 67 (1987), 520–582.
36. 36 Taher, A., Musallam, K.M., El Rassi, F., et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 146 (2009), 569–572.
37. 37 Aydinok, Y., Bayraktaroglu, S., Yildiz, D., Alper, H., Myocardial iron loading in patients with thalassemia major in Turkey and the potential role of splenectomy in myocardial siderosis. J Pediatr Hematol Oncol 33 (2011), 374–378.
38. 38 Garbowski, M.W., Evans, P., Porter, J.B., Residual erythropoiesis protects against cardiac iron loading in transfusion dependent thalassaemia (TDT) by lowering labile plasma iron (LPI) through transient apotransferrin generation. Blood, 126, 2015, 539.